Lin, N.-H. | bioRxiv Science

bioRxiv2026

Interdigitating coiled-coil tetramers define the helical architecture of GFAP filaments in astrocytes

GFAP filaments are core elements of the cytoskeleton in astrocytes, shaping cellular processes and influencing central nervous system function and pathology. How these filaments are built at the molecular level has remained unclear. Using cryo-electron microscopy and cryo-electron tomography, we show that GFAP filaments are helical polymers assembled from extended and twisted coiled-coil tetramers that interdigitate to form a complex filament tube. In the filament lumen, the low-complexity head domains aggregate to form a flexible fibre, while the tail domains extend from the surface and facilitate higher-order bundling of the filaments, indicating that both the low-complexity structural regions and the well-ordered coiled-coils of the filament tube contribute to the unique structure of GFAP filaments. Our findings provide molecular insights into the pathogenesis of Alexander Disease, localising multiple deleterious mutations to the critical interlock interaction between successive tetramers emergent in the final filament assembly.

neuroscience↗

bioRxiv2021

Antisense therapy in a new rat model of Alexander disease reverses GFAP pathology, white matter deficits, and motor impairment.

Alexander disease (AxD) is a devastating leukodystrophy caused by gain of function mutations in GFAP, and the only available treatments are supportive. Recent advances in antisense oligonucleotide (ASO) therapy have demonstrated that transcript targeting can be a successful strategy for human neurodegenerative diseases amenable to this approach. We have previously used mouse models of AxD to show that Gfap-targeted ASO suppresses protein accumulation and reverses pathology; however, the mice have a mild phenotype with no apparent leukodystrophy or overt clinical features and are therefore limited for assessing functional outcomes. In this report we introduce a new rat model of AxD that exhibits hallmark pathology with GFAP aggregation in the form of Rosenthal fibers, widespread astrogliosis, and white matter deficits. These animals develop normally during the first postnatal weeks but fail to thrive after weaning and develop severe motor deficits as they mature, with approximately 15 % dying of unknown cause between 6 to 12 weeks of age. In this model, a single treatment with Gfap-targeted ASO provides long lasting suppression, reverses GFAP pathology, and depending on age of treatment, prevents or mitigates white matter deficits and motor impairment. This is the first report of an animal model of AxD with myelin pathology and motor impairment, recapitulating prominent features of the human disease. We use this model to show that ASO therapy has the potential to not only prevent but also reverse many aspects of disease.

neuroscience↗